To compile the report, researchers examined data from numerous oncology databases detailing medication spending and cancer drug pipelines, among other quantitative measures.
Here are five report findings.
- Worldwide oncology drug spending increased from $91 billion in 2012 to $113 billion in 2016.
- QuintilesIMS projects annual spending growth of 6 percent to 9 percent over the next five years.
- Regulators — including the Food and Drug Administration — approved 68 new cancer treatments since 2011, according to the report.
- There are 631 experimental cancer drugs currently in development.
- The median time for a company to earn a patent for an investigational drug and receive regulatory approval dropped from 10.25 years in 2013 to 9.8 years in 2016, according to the report.
More articles on supply chain:
5 latest FDA approvals
DHL exec: 3 tech solutions innovating healthcare supply chain
Walmart employees to deliver online orders on commute home: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.